Swapna Narla - Founder - US Yantra Life Sciences
The rising complexities surrounding infertility, hormonal imbalance, reproductive wellness, and women’s healthcare have created a growing demand for scientifically driven and trustworthy healthcare solutions. As patients and healthcare professionals seek evidence-based formulations, clinically reliable products, and ethical healthcare solutions, the need for scientifically driven pharmaceutical innovation continues to grow.
Founded in 2025 by Swapna Narla along with Sreekar Peddi, US Yantra Life Sciences Pvt. Ltd. was established with a vision to advance women’s health, fertility care, and specialised healthcare solutions through innovation, scientific excellence, and ethical healthcare practices. Supporting this vision is Dodda Suresh, whose decades of pharmaceutical field experience, scientific understanding, and mentoring capabilities continue to contribute significantly to the organisation’s growth and market development.
With operations spanning India and the USA, a growing workforce of more than 100 employees, and a professional network of over 6000 doctors, the organisation is steadily building its presence across fertility care, PCOS management, menopause support, urogenital health, paediatric care, uro and andro specialities, and advanced healthcare solutions focused on safety, quality, and therapeutic effectiveness.
Sreekar Peddi
At the centre of US Yantra Life Sciences Pvt. Ltd. is Swapna Narla, a dynamic entrepreneur, visionary healthcare strategist, and transformational business leader with over two decades of experience across India and the United States in information technology, software development, healthcare innovation, and multinational business leadership.
Her professional journey combines technology leadership, business strategy, operational excellence, and healthcare innovation. Alongside her expertise in information technology systems, software integration, digital infrastructure, and business process optimisation, she has consistently focused on identifying scalable solutions that improve organisational efficiency, productivity, and long-term growth.
Today, US Yantra Life Sciences continues to focus on differentiated therapeutics, advanced nutraceuticals, probiotics, fertility-supportive healthcare solutions, and research-oriented product innovation through collaboration with highly experienced scientific and pharmaceutical teams.
Ms. Narla is also widely recognised for her multidimensional leadership capabilities, where innovation, technology intelligence, and humanitarian values come together to create meaningful impact. Beyond organisational growth, she remains strongly committed to employment generation, employee empowerment, ethical healthcare accessibility, and long-term societal contribution.
Spiritually grounded and deeply positive in outlook, she strongly believes in value-based leadership, integrity, purposeful growth, and building organisations that positively impact society.
While the company’s broader vision is driven through strategic innovation and healthcare expansion, Dodda Suresh brings more than 25 years of extensive experience in the pharmaceutical and life sciences industry to the organisation.
His journey has been built through continuous hard work, sacrifices, challenges, emotional struggles, and relentless dedication toward healthcare excellence and organisational growth. Over the past two and a half decades, he has travelled across multiple states in India and several international markets, gaining deep exposure to pharmaceutical sales, marketing strategies, doctor engagement, product positioning, distribution systems, and healthcare business development.
His field experience across diverse territories helped him understand market behaviour, prescription trends, patient needs, and scientific product communication at a practical level. Starting his career from the grassroots level, he faced numerous professional and personal challenges with determination and resilience. Through years of fieldwork, strategic execution, and consistent performance, he emerged as a highly successful sales and business development professional known for delivering strong organisational growth and market expansion.
One belief, in particular, became central to the organisation’s larger healthcare philosophy:
“Healthcare is not only about medicines — it is about hope, trust, education, and improving quality of life.”
This perspective continues to shape the organisation’s approach toward fertility management, women’s healthcare, and patient-focused pharmaceutical solutions.
At the core of US Yantra’s operations lies a focused commitment toward fertility care, reproductive wellness, women’s health, and specialised pharmaceutical innovation. Unlike organisations operating across unrelated therapeutic segments, the company has consciously concentrated on healthcare areas that require scientific precision, clinical understanding, and continuous innovation.
Its product and therapeutic focus include female infertility management, male fertility improvement, IVF-supportive therapies, hormonal balance, reproductive wellness, advanced gynaecology care, and speciality healthcare solutions designed to support patient outcomes more effectively.
The organisation’s scientific approach is reflected not only in its formulations but also in the way it engages with healthcare professionals. Rather than depending purely on conventional pharmaceutical promotion, the company places strong emphasis on scientific presentations, clinical discussions, evidence-based communication, and educational awareness.
As Ms. Narla states, “We are not just building a pharmaceutical company; we are building trust, employment opportunities, healthcare value, and a long-term healthcare legacy.”
This philosophy continues to shape the company’s doctor relationships, healthcare collaborations, and product development strategies. By closely working with IVF specialists, gynaecologists, fertility centres, and healthcare professionals, US Yantra seeks to create meaningful value within the reproductive healthcare ecosystem.
Its commitment toward evidence-based formulations and scientific product positioning has also helped strengthen professional trust among doctors and healthcare providers, particularly within fertility and women’s health segments where clinical reliability remains critical.
One of the defining strengths of US Yantra lies in its ability to combine healthcare innovation with technology-driven strategic thinking. With her experience across information technology systems, software integration, digital infrastructure, and business process optimisation, Swapna Narla continues to focus on building scalable operational systems, improving organisational efficiency, and strengthening long-term healthcare growth strategies.
Her multidimensional leadership approach allows the organisation to balance healthcare innovation with operational excellence and sustainable business growth. The company continues to invest in advanced nutraceuticals, probiotics, fertility-supportive healthcare products, wellness-focused solutions, and scientifically differentiated formulations designed to address evolving healthcare needs.
At the same time, the organisation actively monitors developments in fertility science, reproductive medicine, hormonal healthcare, preventive therapeutics, and nutraceutical innovation to stay aligned with future healthcare trends. Its leadership regularly engages with healthcare professionals, fertility specialists, distributors, and scientific communities to better understand changing treatment protocols, patient concerns, and emerging healthcare opportunities.
This forward-thinking and research-oriented culture continues to strengthen the organisation’s ability to adapt to changing industry dynamics while maintaining scientific credibility, innovation, and patient trust.
Like many emerging healthcare organisations, US Yantra faced multiple practical, emotional, and operational challenges during its growth journey. Building trust within the highly competitive pharmaceutical and fertility segments required far more than product visibility or commercial execution.
The organisation recognised early that long-term success in women’s healthcare and fertility management depends on scientific credibility, ethical healthcare practices, product consistency, and strong doctor confidence.
Instead of focusing solely on commercial expansion, the company concentrated on educational engagement with healthcare professionals through scientific discussions and clinical support systems. This approach enabled the organisation to gradually establish stronger doctor relationships and differentiate itself within specialised therapeutic segments.
At the same time, market expansion brought additional operational challenges. Entering new states and regions required understanding varying doctor preferences, regulatory systems, patient expectations, and distribution structures. Years of practical exposure helped the leadership build region-specific strategies and professional networks that supported the organisation’s expansion journey.
Another major challenge involved working within emotionally sensitive healthcare segments such as infertility and reproductive health. Patients seeking fertility support often expect not only clinically effective products but also emotional reassurance, trust, and scientific confidence.
As the company expanded, the leadership also encountered financial pressures, operational uncertainties, emotional struggles, and the hidden sacrifices that often accompany entrepreneurial growth journeys. Reflecting on these experiences, Mr. Suresh shares, “Challenges are temporary, but vision and determination create legacy.”
People development remains one of the strongest pillars of US Yantra’s organisational culture. The leadership team strongly believes that sustainable growth is possible only when employees grow alongside the organisation.
The company focuses not only on hiring skilled professionals but also on developing future leaders through scientific education, mentorship, leadership training, and continuous professional development.
One of Dodda Suresh’s major strengths has been his mentoring capability and pharmaceutical product knowledge. Throughout his career, he has consistently invested time in training junior employees, enhancing communication skills, improving scientific detailing techniques, and guiding individuals toward higher professional responsibilities.
His mentoring approach combines scientific product education, practical field exposure, communication development, emotional motivation, and performance discipline. Over the years, many employees working in entry and mid-level positions have progressed into higher professional roles under his guidance.
At the organisational level, US Yantra continues to maintain a highly motivated and engaged workforce through structured training programs, transparent communication, leadership development initiatives, achievement recognition systems, and opportunities for strategic growth.
The organisation also strongly emphasises employee empowerment, accountability, teamwork, and professional ownership across departments.
“True leadership is not about position, but about responsibility and service.”
This philosophy remains deeply embedded within the company’s work culture and leadership approach.
For US Yantra Life Sciences, success is not measured solely through revenue generation or market share. The organisation defines success through healthcare transformation, scientific excellence, ethical growth, patient outcomes, employment generation, and long-term societal contribution.
Its larger mission involves supporting fertility care, improving reproductive wellness, creating employment opportunities, empowering healthcare professionals, and building a globally respected healthcare institution with strong Indian roots.
As Ms. Narla states, “We believe true success means delivering scientifically driven, ethical, and affordable healthcare solutions in women’s health, infertility, male fertility, gynaecology, and IVF support.”
This vision reflects the organisation’s commitment toward balancing innovation, compassion, scientific advancement, and ethical healthcare delivery.
The company’s long-term “100 Crore Club” mission represents not merely financial ambition but a larger aspiration to build a trusted Indian healthcare brand capable of delivering meaningful impact both domestically and internationally.
Within a relatively short span, US Yantra Life Sciences has already earned several recognitions reflecting its growing influence within the healthcare and life sciences sector.
One of the organisation’s notable achievements came when badminton champion Saina Nehwal recognised the company for its contribution toward healthcare innovation by presenting the Scientific Excellence in Formulation Award at the South India Excellence Awards. The recognition highlighted the organisation’s research-driven formulations, pharmaceutical innovation, and evidence-based healthcare approach.
The company was also honoured with the Best Start-Up Award 2026 by the Global Healthcare and Wellness Awards Committee, presented by the Honorable Minister of Telangana. This award acknowledged the organisation’s rapid growth, specialised healthcare focus, and contribution toward fertility science and women’s healthcare innovation.
Further strengthening its reputation within the healthcare and life sciences sector, US Yantra received the Best Innovative Products Award in the Start-Up Category from the Global Pinnacle Team in the presence of senior IAS officials and distinguished Indian celebrities. The award recognised the company’s scientific innovation, patient-centric formulations, and commitment toward technologically advanced healthcare solutions.
These milestones continue to reinforce the organisation’s vision of building a globally respected healthcare enterprise rooted in innovation, scientific excellence, and ethical values.
Looking ahead, US Yantra believes the future of healthcare will increasingly be shaped by evidence-based medicine, fertility innovation, personalised healthcare, women’s wellness, preventive therapeutics, and scientifically validated nutraceutical formulations.
To position itself for long-term growth, the organisation plans to continue investing in advanced formulations, scientific validation systems, healthcare innovation, talent development, ethical doctor engagement, and future-ready healthcare solutions.
With the combined vision of Swapna Narla, Sreekar Peddi, and the pharmaceutical expertise of Dodda Suresh and Diretor Mani Sai kapil Dodda , the organisation continues progressing toward becoming a globally recognised healthcare company focused on innovation, operational excellence, employment generation, and meaningful societal contribution.
At the same time, the company remains deeply committed to its foundational values of integrity, continuous learning, humanity, ethical growth, and long-term healthcare impact.
As Mr. Suresh reflects, “Building people is the foundation for building a successful organisation.”
With a leadership structure that combines strategic innovation, scientific understanding, humanitarian values, and healthcare-focused growth, US Yantra Life Sciences continues moving steadily toward its vision of creating lasting impact across women’s health, fertility care, and specialised healthcare solutions in India and global markets.